Mark J. Alles

Insider Reports History

Identity 1 fact
Location
Summit, NJ
SEC filing record 1 fact
SEC signature
/s/ Todd Rosenthal, as attorney-in-fact
SEC evidence 1 fact
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Mark J. Alles:

Form 4 holding Director

Syros Pharmaceuticals, Inc.

Security class
Restricted Stock Units
Shares / value
5,334
Estimated value
$11,841
Report date
16 Sep 2023
Price
$2.22
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Turning Point Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
17 Aug 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Mark J. Alles

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .